Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Phase 2 Completed 37 enrolled Revance Therapeutics, Inc.

SequentialOpen-labelTreatment

Summary

This is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxinA in subjects with isolated cervical dystonia (CD).

Timeline

Start: 2015-09
Primary completion: 2016-12-07
Completion: 2017-07-17

Publications

Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, Oh CK, Snyder D, Shears G, Comella C. Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study. Mov Disord Clin Pract. 2018 Apr 26;5(3):273-282. doi: 10.1002/mdc3.12613. eCollection 2018 May-Jun.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Botulinum toxin type A	Protein / enzyme biologic	200 iu	Intramuscular
Subject	Botulinum toxin type A	Protein / enzyme biologic	300 iu	Intramuscular
Subject	Botulinum toxin type A	Protein / enzyme biologic	450 iu	Intramuscular

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Summary

Timeline

Publications

Drugs

Indications